Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Treasury Shares (2020 - 2025)

Protalix BioTherapeutics has reported Treasury Shares over the past 10 years, most recently at $739594.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $739594.0 for Q4 2025, down 14.28% from a year ago — trailing twelve months through Dec 2025 was $739594.0 (down 14.28% YoY), and the annual figure for FY2025 was $739594.0, down 14.28%.
  • Treasury Shares for Q4 2025 was $739594.0 at Protalix BioTherapeutics, down from $862816.0 in the prior quarter.
  • Over the last five years, Treasury Shares for PLX hit a ceiling of $1.2 million in Q4 2023 and a floor of $291474.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $739594.0 (2025), compared with a mean of $705116.2.
  • Biggest five-year swings in Treasury Shares: crashed 36.36% in 2022 and later skyrocketed 302.67% in 2023.
  • Protalix BioTherapeutics' Treasury Shares stood at $458027.0 in 2021, then crashed by 36.36% to $291474.0 in 2022, then skyrocketed by 302.67% to $1.2 million in 2023, then dropped by 26.49% to $862816.0 in 2024, then fell by 14.28% to $739594.0 in 2025.
  • The last three reported values for Treasury Shares were $739594.0 (Q4 2025), $862816.0 (Q4 2024), and $1.2 million (Q4 2023) per Business Quant data.